CA-INGRAM-MICRO-INC
For the first time in its history, Ingram Micro Inc. is taking its ONE event to a fully global audience in a completely online interactive experience. Bringing together APAC ONE, EMEA ONE, LATAM ONE and North America ONE enable Ingram Micro to support multiple time zones and languages, while hosting 12 keynotes, 150 sessions and speakers and attendees from more than 60 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005717/en/
As part of the experience, localized content and sessions will be provided for each region. Targeted sessions will also be held pre- and post-experience for special guests attending by countries and communities including Ingram Micro’s SMB Alliance and Trust X Alliance . Ingram Micro channel partners and providers are encouraged to register now at https://imaginenext.ingrammicro.com/one .
Ingram Micro’s executive leadership team will kick off this year’s online experience starting with opening remarks from CEO Alain Monié and EVP and President Paul Bay. Additional event highlights include:
- Fireside chats with Cisco CEO Chuck Robbins and IBM President Jim Whitehurst
- Futurist keynote featuring 311 Institute Founder and CEO Matthew Griffin
- Diversity and Inclusion Keynote from Former NASA Space Science Education Lead Hakeem Oluseyi
- Technology and trends keynote from IDC Group Vice President Michelle Bailey
- Executive addresses from global business leaders including Ingram Micro’s SVP of Marketing Jennifer Anaya, EVP Global Cloud Nimesh Davé, and VP of Global Partner Engagement and IoT Sabine Howest
- Special guests including a GRAMMY award winning musician and bands from around the globe
- An inspired address from one of the best-selling authors, and optimistic motivational speakers on the planet
A complete list of speakers and sessions, including the identities of the above artists and motivational speaker, is noted here . Additionally, several key Ingram Micro announcements and strategic initiatives are expected to launch leading up to and throughout the event, including community announcements from SMB Alliance and Trust X Alliance . Live networking, virtual happy hours and AI-powered business matchups are also on tap for attendees.
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers,” said Bay. “Together we are working smarter, harder and with a greater purpose. Ingram Micro and the ecosystem of partner excellence we support has never been more relevant to the vitality and success of today’s business landscape locally, regionally and globally…and we’re ready to do even more.”
Channel press and analysts are welcome to register and attend designated sessions of the Nov. 4-5 Ingram Micro ONE Experience.
For more information visit https://imaginenext.ingrammicro.com/one .
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005717/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom